San Donato Hospital
| Італія | Туреччина | Україна | |
| Плазмаферез | від $2,200 | від $1,200 | від $700 |
| Внутрішньовенна терапія куркуміном | від $450 | від $350 | від $400 |
| Інфузія донорської пуповинної крові | від $10,000 | від $5,000 | від $3,000 |
| Терапевтичний аферез | від $2,200 | від $1,350 | - |
| Селективний аферез | від $3,100 | від $1,550 | - |
Ви не сплачуєте за послуги Bookimed. Ціни на лікування імунології відповідають прайс-листу клініки. Ви сплачуєте безпосередньо в клініці. Доступна оплата частинами.
Bookimed піклується про вашу безпеку. Ми співпрацюємо лише з медичними закладами, які дотримуються високих міжнародних стандартів у галузі імунології та мають необхідні ліцензії для обслуговування пацієнтів з різних країн.
Bookimed надає безкоштовну експертну підтримку. Особистий лікар-координатор супроводжує вас до, під час та після лікування, вирішуючи будь-які питання. Ви ніколи не залишитеся наодинці, проходячи імунологічні процедури в іншій країні.
Професор Аіуті очолює новаторські дослідження в галузі генної терапії рідкісних імунодефіцитів у лікарні Сан-Раффаеле, маючи понад 180 публікацій у цій галузі.
Визнаний «Світовим експертом із захворювань, пов'язаних з IgG4» за версією Expertscape, доктор Делла Торре очолює спеціалізовані клініки в лікарні Сан-Раффаеле.
Advanced cancer immunotherapies like CAR T-cell therapy are available in Italy. The Italian Medicines Agency (AIFA) authorizes these treatments for specific blood cancers. Leading centers in Milan and Rome provide clinical access. Specialized facilities like San Raffaele also offer advanced gene therapies.
Bookimed Expert Insight: Milan has become the primary hub for Italian immunotherapy. Clinics like San Raffaele combine research with clinical care, serving 300,000 patients annually. Our data shows these IRCCS-accredited centers often manage the highest volume of complex immune cases. Patients should target these large research hospitals to find the widest range of active clinical trials.
Patient Consensus: Patients note that while treatment is highly effective for blood cancers, the approval process can take three months. It is important to prepare for travel to major northern hubs like Milan because specialized care is rarely available at smaller local hospitals.
San Raffaele Hospital and Humanitas Research Hospital in Milan are globally recognized for treating rare immune disorders. San Raffaele pioneered the world first stem cell gene therapy for ADA-SCID. These centers hold IRCCS accreditation. This status marks them as premier Italian research institutes for molecular medicine.
Bookimed Expert Insight: Data shows that Milan is the primary hub for rare immunology. Clinics like San Raffaele and San Donato serve 300,000 patients yearly. Their IRCCS status is a key quality signal. This accreditation means they receive direct government funding for advanced clinical trials. Patients should prioritize these research-heavy centers for complex or undiagnosed immune conditions.
Patient Consensus: Patients note that San Raffaele is a top choice for primary immunodeficiencies and advanced trials. Many emphasize its collaboration with international institutions as a major factor for choosing Milan for rare disease care.
Italy offers new EMA-approved biologics like Anifrolumab for lupus and Bimekizumab for psoriatic arthritis. Targeted oral JAK inhibitors including Upadacitinib and Filgotinib are also widely available. These therapies are accessible through specialized IRCCS centers like San Raffaele and Humanitas Research Hospital in Milan.
Bookimed Expert Insight: Data from Milanese centers shows a high concentration of expertise in rare autoimmune conditions. Dr. Emanuele Della Torre at San Raffaele is a recognized global expert in IgG4-related diseases. Patients often find faster access to clinical trials and the latest AIFA-approved molecules at these research-heavy IRCCS institutions compared to general hospitals.
Patient Consensus: Patients note that starting documentation of previous treatment failures immediately helps speed up the approval process. Those treated in Northern Italy often report significantly shorter wait times for the newest drug listings than in Southern regions.
Allergen immunotherapy (AIT) accessibility in Italy remains highly variable due to regional reimbursement policies. The National Health System (SSN) covers grass pollen treatments for specific groups. However, patients often face full costs for other allergens like house dust mites depending on their local residence.
Bookimed Expert Insight: Patients seeking AIT should prioritize clinics with IRCCS accreditation, such as San Raffaele or San Donato. This Italian Ministry of Health certification signals a research-driven environment. These institutions often handle 300,000+ patients annually. Their high volume and academic links, featuring experts like Dr. Emanuele Della Torre, ensure access to the latest immunological protocols.
Patient Consensus: Patients note that sublingual therapy is the most convenient option for home use. Many emphasize the need to self-advocate or seek second opinions to successfully navigate the public reimbursement process.